Search Femetric

Search peptides, goals, protocols and references

PROTOCOL LIBRARY

Reference protocols, clearly organized.

Browse supplied research-reference records alongside source-indexed study structures. Missing fields remain unfilled rather than inferred.

01
RESEARCH REFERENCE · Tendon, ligament, muscle, and soft-tissue healing · Gut mucosal repair · General recovery and inflammation support

BPC-157

250–500 mcg/day

Subcutaneous (near injury or systemic) · Daily or split · 4–8 weeks (up to 12 weeks for chronic issues)
02
STACK / BLEND · Regenerative + stronger anti-inflammatory / gut support

KLOW (GLOW + KPV)

GLOW blend plus KPV for added anti-inflammatory coverage.

4–8 weeks
03
RESEARCH REFERENCE · Skin quality, firmness, and collagen · Wound healing and anti-inflammatory effects · Hair and tissue regeneration

GHK-Cu

1–2 mg SC

Subcutaneous (or topical) · Daily · 4–8 weeks
04
RESEARCH REFERENCE · Significant body-weight reduction · Appetite suppression + increased energy expenditure · Glycemic control and liver-fat reduction

Retatrutide

1–6 mg (most common practical range)

Subcutaneous · Once weekly · Ongoing / multi-month
05
RESEARCH REFERENCE · Antioxidant / detox support · Liver health · Immune and skin support

Glutathione

Oral GSH 500–1000 mg + NAC 600–1800 mg; injectable 200–1200 mg

Oral (liposomal preferred) or SC/IM · Daily oral or 2–3× weekly injectable · Ongoing or 8–12 weeks
06
RESEARCH REFERENCE · Insulin sensitivity and metabolic health · Exercise capacity and mitochondrial function · Potential healthspan support (preclinical)

MOTS-c

5–10 mg

Subcutaneous · 2–3× weekly or short pulsed courses · 6–12 weeks or short pulsed cycles (e.g., 4 injections over 20 days) repeated 2–4× per year
07
RESEARCH REFERENCE · Weight loss · Type 2 diabetes · Metabolic health

Tirzepatide

2.5 → 15 mg

Subcutaneous · Once weekly · Ongoing
08
RESEARCH REFERENCE · Weight loss · Type 2 diabetes · Cardiovascular risk reduction

Semaglutide

0.25 → 2.4 mg

Subcutaneous · Once weekly · Ongoing
09
RESEARCH REFERENCE · Appetite suppression and weight loss · Complementary to GLP-1 agonists

Cagrilintide

Titrate to 2.4 mg (up to 4.5 mg studied)

Subcutaneous · Once weekly · 26–68+ weeks or ongoing
10
STACK / BLEND · Superior weight loss compared with either agent alone · Glycemic and metabolic improvement

Cagrilintide + Semaglutide (CagriSema)

Typically escalate both to 2.4 mg each

Subcutaneous · Once weekly · 68+ weeks in trials or ongoing
11
RESEARCH REFERENCE · Visceral adipose tissue (VAT) reduction · Improved lipid profiles · Potential hepatic-fat reduction

Tesamorelin

1 mg (Week 1) → 2 mg daily

Subcutaneous · Once daily · 12–26 weeks (extendable to 52 weeks under supervision)
12
RESEARCH REFERENCE · Fat loss · Potential joint/cartilage support

AOD 9604

250–500 mcg

Subcutaneous · Daily · 8–12 weeks
13
STACK / BLEND · Combined skin + soft-tissue repair

GLOW (GHK-Cu + BPC-157 + TB-500)

Dose to deliver meaningful amounts of each (commonly ~2.5 mg GHK-Cu + 500 mcg BPC + 500 mcg TB per injection)

Subcutaneous · Daily · 4–8 weeks
14
RESEARCH REFERENCE · Gut inflammation / IBD-type support · Systemic anti-inflammatory

KPV

Oral 500 mcg–1 mg; SC 250–500 mcg

Oral (preferred for gut) or subcutaneous · 1–2× daily · 4–8 weeks
15
RESEARCH REFERENCE · Soft-tissue, tendon, ligament, and muscle recovery · Systemic healing support

TB-500

2–2.5 mg (loading), 2 mg (maintenance)

Subcutaneous · Loading then maintenance · 8–12 weeks total (4–6 weeks loading + maintenance)
16
RESEARCH REFERENCE · Immune optimization and support · Adjunctive use in chronic viral or immune-compromised states

Thymosin Alpha-1

1.6 mg (clinical standard)

Subcutaneous · 2× weekly (or 5-on/2-off in some protocols) · 8–16 weeks (or longer for chronic use)
17
RESEARCH REFERENCE · Mitochondrial function and energy · Muscle energetics and exercise capacity · Investigational in mitochondrial myopathies and related conditions

SS-31 (Elamipretide)

5–40 mg (clinical trials commonly used 40 mg; community often lower)

Subcutaneous · Once daily · 4–12 weeks (or longer under supervision in clinical contexts)
18
RESEARCH REFERENCE · Cellular energy and mitochondrial support · Recovery, cognitive clarity, and longevity support

NAD+

SC 50–200 mg; higher for IV

Subcutaneous (most practical for self-administration) · 2–3× weekly (SC) or periodic higher-dose sessions · 8–12 weeks or ongoing
19
RESEARCH REFERENCE · Longevity / telomere and pineal support · Circadian and melatonin regulation

Epitalon (Epithalon)

5–10 mg per day

Subcutaneous · Daily during short course · 10–20 consecutive days per course
20
RESEARCH REFERENCE · Hypoactive sexual desire / arousal support

PT-141 (Bremelanotide)

0.5–1.75 mg

Subcutaneous · As needed · As needed (max 1 dose/24 h, ≤8 doses/month recommended)
21
RESEARCH REFERENCE · Reproductive hormone axis / libido research

Kisspeptin-10

50–200 mcg

Subcutaneous · Pulsed (every other day or short cycles) · 2–6 weeks short cycles
22
RESEARCH REFERENCE · Pulsatile GH release · Recovery, sleep, and body composition

Ipamorelin

100–300 mcg per injection

Subcutaneous · 1–3× daily · 8–12 weeks
23
RESEARCH REFERENCE · Sustained GH optimization · Recovery, body composition, and anti-aging support

CJC-1295 (with DAC)

0.5–2 mg

Subcutaneous · 1–2× weekly · 8–12 weeks
24
RESEARCH REFERENCE · Natural GH optimization · Recovery, sleep quality, and body composition

Sermorelin

200–500 mcg

Subcutaneous · Once daily (or 5–7 nights per week) · 3–6 months continuous or 8–12 weeks with breaks
25
RESEARCH REFERENCE · Focus, memory, and cognitive performance · Neuroprotection

Semax

200–600 mcg

Intranasal preferred; subcutaneous possible · 1–3× daily · Days to several weeks
26
RESEARCH REFERENCE · Anxiety reduction without sedation · Cognitive/stress support

Selank

250–500 mcg (up to ~900 mcg/day in Russian protocols)

Intranasal preferred; SC possible · 2–3× daily · 10–14 day courses
27
STACK / BLEND · Stubborn tendon, ligament, muscle, or joint injuries

BPC-157 + TB-500 (Wolverine stack)

BPC 250–500 mcg/day; TB 2–2.5 mg loading → 2 mg maintenance

Subcutaneous (can often be mixed in same syringe) · BPC daily or split; TB loading then maintenance · 6–12 weeks
28
STACK / BLEND · Maximized pulsatile GH release · Recovery, body composition, sleep, and performance

CJC-1295 (no DAC) + Ipamorelin

100–300 mcg of each per injection

Subcutaneous (commonly mixed in the same syringe) · 1–3× daily · 8–12 weeks
29
RESEARCH REFERENCE · Gradual, even tanning · Photoprotection

Melanotan 1 (Afamelanotide / MT-1)

100–500 mcg

Subcutaneous · Loading then maintenance · Loading 2–4 weeks then maintenance as needed
30
RESEARCH REFERENCE · Faster/deeper tanning · Appetite and libido side effects

Melanotan 2 (MT-2)

0.25–1 mg

Subcutaneous · Daily loading then maintenance · Loading 1–3 weeks then maintenance
31
RESEARCH REFERENCE · Muscle growth and recovery support

IGF-1 LR3

20–100 mcg

Subcutaneous or intramuscular · Daily or post-workout · 4–6 weeks
32
RESEARCH REFERENCE · Sleep quality / delta-wave support

DSIP

100–300 mcg

Subcutaneous · Daily or 5-on/2-off · 4–8 weeks
33
KLOW (GLOW + KPV) · COMPONENT LITERATURE

Component research context

KLOW is not one standardized scientific formulation. No administration structure is shown until an exact formula and direct source are indexed.

Formulation dependent · Not established
34
Retatrutide · PUBLISHED STUDY

1 mg fixed weekly

Published fixed-dose arm from the 48-week Phase 2 obesity trial.

Subcutaneous · Once weekly
35
Retatrutide · PUBLISHED STUDY

4 mg target · 2 mg initial

Published 4 mg target arm beginning at 2 mg, with escalation at a four-week interval.

Subcutaneous · Once weekly
36
Retatrutide · PUBLISHED STUDY

4 mg fixed weekly

Published 4 mg arm that began at the target dose.

Subcutaneous · Once weekly
37
Retatrutide · PUBLISHED STUDY

8 mg target · 2 mg initial

Published 8 mg target arm beginning at 2 mg. Exact intermediate stages are pending direct source extraction.

Subcutaneous · Once weekly
38
Retatrutide · PUBLISHED STUDY

8 mg target · 4 mg initial

Published 8 mg target arm beginning at 4 mg. Exact intermediate stages are pending direct source extraction.

Subcutaneous · Once weekly
39
Retatrutide · PUBLISHED STUDY

12 mg target · 2 mg initial

Published 12 mg target arm beginning at 2 mg. Exact intermediate stages are pending direct source extraction.

Subcutaneous · Once weekly
40
Tirzepatide · PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous · See indexed source
41
Semaglutide · PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous · Oral · See indexed source
42
Cagrilintide · PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous · See indexed source
43
Cagrilintide + Semaglutide (CagriSema) · PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous · See indexed source
44
Tesamorelin · PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous · See indexed source
45
AOD 9604 · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Oral research · Subcutaneous research · See indexed source
46
5-Amino-1MQ · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Source dependent · See indexed source
47
Survodutide · PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous · See indexed source
48
Mazdutide · PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous · See indexed source
49
Pemvidutide · PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous · See indexed source
50
Liraglutide · PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous · See indexed source
51
AHK-Cu · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Topical research · See indexed source
52
GLOW (GHK-Cu + BPC-157 + TB-500) · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Source dependent · See indexed source
53
KPV · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Source dependent · See indexed source
54
TB-500 · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Source dependent · See indexed source
55
Thymosin Alpha-1 · PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous · See indexed source
56
SS-31 (Elamipretide) · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous · See indexed source
57
NAD+ · PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Source dependent · See indexed source
58
Epitalon (Epithalon) · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Source dependent · See indexed source
59
Humanin · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Source dependent · See indexed source
60
PT-141 (Bremelanotide) · PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous · See indexed source
61
Kisspeptin-10 · PUBLISHED STUDY

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Intravenous research · See indexed source
62
Ipamorelin · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Intravenous research · Subcutaneous research · See indexed source
63
CJC-1295 (with DAC) · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous research · See indexed source
64
Sermorelin · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Subcutaneous · See indexed source
65
Semax · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Intranasal research · See indexed source
66
Selank · LITERATURE-DERIVED REFERENCE

Source-linked research context

No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.

Intranasal research · See indexed source
NEXT RESEARCH ACTION
Was this useful?